Lanean...
SAT-516 A Severe Case of Pembrolizumab-Induced Thyroiditis
Pembrolizumab, a programmed death 1 (PD-1) inhibitor used for advanced malignancies, can be associated with thyroid dysfunction.(1-2) Specifically, thyroiditis occurs in nearly 2.3% of individuals.(2) The hyperthyroid phase is typically non-severe, requiring only beta blockers. Our case illustrates...
Gorde:
| Argitaratua izan da: | J Endocr Soc |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208842/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1895 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|